I n order for medication to be prescribed effectively and safely, many medications require monitoring. Medication monitoring may involve blood tests but can also include other monitoring such as blood pressure, weight or electrocardiograms. Monitoring can be required before initiating medication, soon after starting, or regularly over the course of treatment. Ensuring that this monitoring has been undertaken is an important part of medication review involving repeat prescribing. The General Medical Council-funded PRACtICe study looked at prescribing and monitoring errors in primary care. Out of the 302 errors identified, 55 (18%) were monitoring errors. Of those drugs that required blood test monitoring, 7% of prescriptions contained a monitoring error. This article gives the reader opportunities to reflect upon different scenarios that involve medication that requires monitoring decisions and how monitoring could be managed in primary care. There are also suggestions for additional continuing professional development activities.
The GP curriculum and providing the right monitoring Contextual statement 2.04: Enhancing professional knowledge requires GPs to provide effective and evidence-based prescribing, adhering to the General Medical Council's principles of good medical prescribing.
Clinical example 3.20: Care of people with musculoskeletal problems requires GPs to apply local sharedcare guidelines for safe prescribing and monitoring of disease-modifying anti-rheumatic drugs Prescribers are responsible for ensuring that the medication they prescribe is safe for the patient to continue taking and is having the desired effect. If for any reason the correct monitoring cannot be undertaken, the prescriber must consider whether it is safe to continue prescribing. General Medical Council (GMC) guidance states that (GMC, 2013) :
Whether you prescribe with repeats or on a one-off basis, you must make sure that suitable arrangements are in place for monitoring, follow up and review, taking account of the patients' needs and any risks arising from the medicines. 
Appropriate monitoring of medication includes:
. Ensuring a medication is monitored and reviewed correctly after initiation or a change in dosage, e.g. angiotensin-converting enzyme inhibitors . Ensuring all necessary monitoring is scheduled and undertaken for medications that are prescribed in the longer term, e.g. checking renal function and blood pressure . Ensuring medication is not continued longer than necessary, e.g. iron supplementation . Ensuring medication is prescribed at the optimal dosage to obtain the required clinical effect, e.g. anti-hypertensive therapy Useful summaries regarding monitoring requirements have been produced by several medicine management services. A list of some of these resources can be found in Box 1.
The PRACtICe study (Avery et al., 2012) reviewed practices and their monitoring requirements for a specific list of medications. The list covered the monitoring required before and after initiation as well as long-term monitoring (see Tables 1 and 2) .
When monitoring is necessary, it is important to undertake the appropriate tests at the correct intervals. The frequency required may change with the clinical situation or the diagnosis. It should be noted that the guidance on monitoring, and especially the frequency that is recommended, often varies between resources.
The Quality and Outcomes Framework (QOF) is an incentive scheme for GP practices with indicators that relate to patient care. Currently, for many long-term conditions, the QOF indicators also include aspects relating to the monitoring of medication. In addition to QOF indicators practices may agree to take part in enhanced services that may involve medication monitoring.
The systems and processes that practices use to facilitate the monitoring of prescribing can vary widely. It is important that all new members of staff familiarise themselves with local protocols so that errors are not made on the basis of assumptions.
Medication reviews are the ideal time to ensure that all monitoring requirements have been met to ensure safe and effective continued prescribing. Even if the practice has recall systems in place for monitoring, the medication review is an important safety net to ensure all the different monitoring requirements have been fulfilled. The following case studies help to show how some of the principles described above may be put into action.
Box 1. Useful resources for medication monitoring.
. Patients prescribed angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) require monitoring of renal function, electrolytes and blood pressure. These medications can cause an increase in potassium levels and a severe reduction in renal function. ACE inhibitors and ARBs can be used in renal impairment although dosages may need adjustment. ACE inhibitors and ARBs are contra-indicted in reno-vascular disease, however, where their initiation will cause a significant reduction in renal function.
Furosemide, along with all diuretics, can change the levels of electrolytes. It should also be noted that loop diuretics (to a lesser extent than thiazide diuretics) can exacerbate diabetes. Higher doses of loop diuretics may be needed in moderate to severe renal impairment. All diuretics will lower blood pressure so this should also be monitored. The use of a beta-blocker such as bisoprolol requires the routine monitoring of blood pressure only in this patient.
With respect to the frequency of monitoring for Mr Waterford, the NICE (2010) guidance for chronic heart failure recommends that monitoring should take place at least 6 monthly in patients with stable heart failure, which would include a minimum of blood pressure, renal function and electrolytes.
Metformin requires dose adjustment or stopping in renal impairment and therefore the BNF recommends measuring renal function prior to treatment and then at least yearly (BMJ Group & Pharmaceutical Press, 2013c) . Gliclazide is principally metabolised in the liver and therefore the dose should be reduced or the medication avoided for patients with liver impairment. Lower doses may also be required in renal impairment. The effectiveness of gliclazide and metformin should be monitored by measuring the level of glycated haemoglobin (HbA1c). NICE (2009) guidance recommends HbA1c is measured every 2 to 6 months until the patient is stable and then 6 monthly (NICE, 2009 ).
Mr Waterford would be included on two chronic disease registers at the practice due to having diabetes and heart failure. Take time to understand the chronic disease recall systems in place at your practice including:
. How are patients recalled for a chronic disease review and how often? . What monitoring is undertaken at each chronic disease review and how are the results reviewed and feedback given to the patient? . What happens if a patient does not attend for a review when requested will they be followed up? . Do chronic disease reviews link up with the medication review system? , 2008) . Therefore, as Mr Waterford is on combination treatment with an ACE inhibitor as well as a loop diuretic, renal function and electrolytes should be checked at 5 to 7 days after the dosage increase.
If Mr Waterford did not return for his blood pressure check and blood test, or for his review with the GP, it is important that the medications do not continue to be supplied without a GP being aware of the lack of follow-up monitoring. Therefore, to prescribe the increased dose of furosemide safely, the prescriber could:
. Schedule a blood test for urea and electrolytes and estimated glomerular filtration rate (eGFR) at 5 to 7 days after the increase in dose . Schedule a review appointment within 2 weeks to monitor the effectiveness of the dose change and ensure the results have been received . Limit the initial supply of medication to 14 or 28 days depending on the patient's previous history with diuretics . Prescribe the initial supply as an acute prescription as this prevents further prescriptions being issued without notification to a GP Case study 3. Monitoring requirements for patients on long-term medications.
For each of the following medications consider the correct routine monitoring and frequency of monitoring for a patient that has been taking the medication for over a year. Find out whether the practice in which you are currently working has any systems in place to ensure that regular monitoring occurs for patients on these medications. Some of the following medication will have QOF indicators that relate to their monitoring requirements:
. Mesalazine for inflammatory bowel disease . Levothyroxine . Anti-psychotics (with the exception of clozapine which has a particularly strict blood testing protocol due to the risk of neutropenia and agranulocytosis which can be fatal) . Minocycline for acne . Carbamazepine for epilepsy . Lithium . Amiodarone . Methorexate.
Comment: In relation to the use of mesalazine (an aminosalicylate) for inflammatory bowel disease, renal function should be monitored before starting treatment, then at 3 months, then annually during treatment (BMJ Group & Pharmaceutical Press, 2013d). The British Society of Gastroenterology (BSG) guidelines recommend (Mowat et al., 2010) :
Annual measurement of creatinine is sensible, although there is no evidence that monitoring is necessary or effective at preventing renal impairment. Aminosalicylates should be stopped if renal function deteriorates.
It should be noted that this advice is different from the SPC for Asacol Õ (last updated 1st May 2010) which recommends (Datapharm Communications Ltd, 2013b):
Patients on mesalazine should have renal function monitored (with serum creatinine levels measured) prior to starting treatment. Renal function should then be monitored periodically during treatment, for example every 3 months for the first year, then 6 monthly for the next 4 years and annually thereafter, based on individual patient history. Blood dyscrasias are also a possible effect with mesalazine. However, no routine blood tests are recommended. The BNF recommends that the patient should be advised to (BMJ Group & Pharmaceutical Press, 2013d):
Report any unexplained bleeding, bruising, purpura, sore throat, fever and malaise that occur during treatment. A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia. Complex blood test monitoring is required for antipsychotics and detailed requirements for individual anti-psychotics can be found in the BNF (BMJ Group & Pharmaceutical Press, 2013e Due to risk of hepatotoxicity and systemic lupus erythematosus, the BNF advises that if treatment is continued for longer than 6 months the patient should be monitored every 3 months for these conditions (BMJ Group & Pharmaceutical Press, 2013f) .
In relation to carbamazepine, the need for monitoring is not clear cut. For anti-epileptic drugs in general the NICE epilepsy guidance notes that 'Regular blood test monitoring in adults is not recommended as routine, and should be done only if clinically indicated' (NICE, 2012) . With carbamazepine it is important to be aware of the risks of serious blood dyscrasias and hepatic impairment and to check full blood count and liver function tests if there are any symptoms or signs of these.
Lithium has a narrow therapeutic window and therefore lithium concentration needs to be monitored.
Once stable, lithium concentration should be assessed every 3 months. Lithium concentration should be measured at 12 hours after the last dose. Lithium can cause changes to thyroid function and renal function. Lithium excretion is also reduced in renal impairment which may cause toxicity. In a stable patient thyroid function tests and renal function should be monitored every 6 months (BMJ Group & Pharmaceutical Press, 2013g) .
Amiodarone is known to cause hepatotoxicity and therefore liver function tests should be performed every 6 months in the stable patient. In addition, the BNF notes that both hypothyroidism and hyperthyroidism may occur in patients taking amiodarone and advises blood tests every 6 months for thyroxine (T4), tri-iodothyronine (T3), and TSH (thyrotrophin, TSH) (BMJ Group & Pharmaceutical Press,2013h) .
In relation to methotrexate, the BNF advises that patients taking low-dose methotrexate should have 'full blood count and renal and liver function tests before starting treatment and repeated every 1-2 weeks until therapy stabilised, thereafter patients should be monitored every 2-3 months'. (BMJ Group & Pharmaceutical Press, 2013i) . The BNF does, however, also acknowledge that local protocols for the frequency of monitoring vary. Methotrexate is usually prescribed in primary care following a shared care protocol for either a rheumatology or dermatological indication. In some cases the frequency of monitoring advised by the shared care protocols may differ depending on the indication (i.e. rheumatology or dermatology).
Many practices have set up regular searches that are run monthly for medication such as methotrexate, warfarin and lithium to identify any patients on these medications who are overdue a blood test.
Once created the searches can be easily run by a suitable member of the reception or administration team and forwarded to a named GP.
Case study 4. Practice systems to avoid monitoring errors.
Consider the following accounts relating to monitoring failures. 1. The following monitoring failure is based on an error found in the GMC PRACtICe study (Avery et al., 2012) . Mrs Zuzarte is a 93-year-old patient on warfarin. The last documented INR on the clinical system was more than a year previously. Mrs Zuzarte had failed to attend three consecutive anticoagulant appointments, but warfarin prescriptions continued to be issued by the practice. 2. Mr Dalton is taking methotrexate for psoriasis. He has a repeat prescription issued by his GP as agreed with the consultant (following a shared care protocol). He is required to have 3 monthly blood tests. Mr Dalton is seen for an acute chest infection and the GP realises that the patient has not had a blood test taken in 5 months, although he has continued to collect his medication every month. Nobody has been in touch with him.
Reflect on the systems in place within your practice and whether either of the above situations (or one that is similar) could occur without the prescriber being alerted or the patient being contacted and reminded to attend for a blood test. Are there any changes in systems or processes that could make the system more robust?
Comment: It is important to be aware of the systems and processes a practice has to help monitor medications, and to which patients they will apply. Some clinical computer systems help to alert prescribers to the most recent test results (e.g. an INR for patients taking warfarin) and let prescribers know if the test is overdue.
In both the scenarios in this exercise the patients would have been made aware of the requirement for monitoring to be undertaken. For patients taking methotrexate or warfarin, they are also likely to be .. ................................................................................................................................................................................................................................................ ............................................................................................................................................................................................................................ aware of the possible consequences of failing to have the monitoring undertaken. It could be argued that patients should take some responsibility for their own health and the management of their medication. However, the GMC guidance (GMC, 2013) states:
520
You are responsible for any prescription you sign, including repeat prescriptions for medicines initiated by colleagues, so you must make sure that any repeat prescription you sign is safe and appropriate.
It can therefore be understood that before signing a prescription for an item such as warfarin the prescriber should be confident that monitoring is up to date and has been reviewed. Some medications, including warfarin, methotrexate, amiodarone and lithium require very specific monitoring, the failure of which can lead to serious adverse consequences. Alongside robust processes within the practice, the clinical computer system may be used to assist in this area. For example, it could be used as in the following. 1. To set-up searches on the system for methotrexate and similar medication in order to identify patients who are overdue on their routine blood tests. These searches can be performed monthly. Once organised, the searches can be run as part of the routine practice work by administrative staff with the search results being given to allocated clinical staff for follow-up. 2. To restrict the amount of medication supplied on repeat to the frequency of monitoring. For example, the supply of methotrexate could be re-authorised for 3 months when acceptable blood tests have been reviewed. This ensures a prescriber will receive a query if methotrexate is requested by the patient after the 3 month supply without the correct blood tests being taken.
Additional CPD activity: Ensure you are familiar with the available drug monitoring features available on your clinical system: . Does the system alert you to overdue monitoring in any way? . Does your practice run regular searches on medication such as methotrexate and warfarin? . If so, which medication is it undertaken for and how does the system work? . If the practice does not use searches in this way investigate whether it would be useful and if so, work with the practice to implement a system
Case study 5. Failure to request monitoring.
Mrs James is a 69-year-old lady who has had arthritis for many years. Her current repeat medication is shown in Fig. 2 .
Mrs James has good pain relief from her current medication and therefore has not attended the practice for 14 months (when she saw a GP trainee with a chest infection). Mrs James has not had any blood monitoring undertaken in the last 18 months (when her blood pressure and electrolytes were within normal limits and her eGFR was 52 ml/min/ 1.73 m 2 ). Using available resources (e.g. those in Box 1), consider what you would recommend for Mrs James.
Comment: This scenario raises several issues: is any monitoring required? If so, why has it not been done? Also, is the current medication still suitable for the patient?
Mrs James is an elderly patient on a long-term nonsteroidal anti-inflammatory drug (NSAID) with reduced renal function. James age and current therapy it would be advisable to check renal function as least annually. CKD monitoring is also included in the QOF indicators. It is worth noting that the BNF advises that 'NSAIDs should be avoided if possible or used with caution in patients with renal impairment' (BMJ Group & Pharmaceutical Press, 2013j) .
In this case the patient had not attended the practice for a medication review, and is only on three medications. It is sometimes easier to monitor patients that attend the practice frequently, have multiple co-morbidities or who are on multiple medications as there are systems in place within the practice to do so.
A suggested plan for Mrs James would be the following. 1. Check her renal function and explain her CKD status including the need to repeat blood tests every 6 months. Ensure Mrs James is on the recall list for CKD monitoring. 2. Explain the issues regarding the use of NSAIDs in a lady of her age and with her renal function and explore trying alternative pain killers and/or reducing the dose of ibuprofen used.
Additional CPD activity: Use the clinical computer system to run a search to identify all patients aged over 65 years in the practice who are prescribed an NSAID on repeat. Check that their renal function has been measured in the last year. Identify patients with an eGFR of less than 50 ml/min/1.73 m 2 and review to ensure prescribing is still appropriate at their current dosage.
Use the clinical computer system to run a search to identify all patients aged over 65 years on repeat prescription for an NSAID who are not prescribed gastroprotection. Review these patients to see if the NSAID is still required and if so, whether gastric protection should be initiated.
Key points
. When prescribing a medication, it is necessary to ensure that all of the monitoring activities appropriate to that medication can be fulfilled . The BNF contains guidance on prescription monitoring, but it is often beneficial to consult additional sources, such as local practice guidelines and shared care protocols; familiarise yourself with the appropriate monitoring requirements of commonly prescribed drugs . As well as ensuring that appropriate monitoring takes place around initiation and dose changes, prescribers should plan for the appropriate longterm monitoring of drugs . Even if your practice has robust monitoring procedures, make use of patients' medication reviews to ensure that the correct monitoring has occurred . Certain medications such as warfarin are associated with particularly serious monitoring errors. Prescribers should be vigilant when reviewing patients receiving warfarin, and ensure that monitoring systems are robust
